New antibody drug aims to halt Scleroderma's damage

NCT ID NCT06843239

Ongoing Disease control Sponsor: Zura Bio Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This Phase 2 trial tests a drug called tibulizumab in 80 adults with systemic sclerosis, a disease that causes skin thickening and can damage organs. Participants first receive either the drug or a placebo for 24 weeks, then everyone who continues gets the drug for another 28 weeks. The main goal is to see if the drug reduces skin thickness and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tibulizumab (an antibody that targets BAFF and IL-17)
What this could lead to: If successful, this could point toward a new treatment option to control skin thickening and lung damage in systemic sclerosis.
What could go wrong: This is an early Phase 2 trial with only 80 participants, so results may not apply to everyone. The drug may not improve symptoms or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease diffuse scleroderma immune system disorder interstitial lung disease scleroderma skin disorder systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLERODERMA SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

AES - AS - Clinica Mayo de Urgencias

San Miguel de Tucumán, T4000IHE, Argentina
Aberdeen Royal Infirmary

Aberdeen, AB25 2ZN, United Kingdom
Aintree University Hospital

Liverpool, L9 7AL, United Kingdom
CTR Estudios Clinicos

Santiago, 7500000, Chile
Center for Clinical and Basic Research (CCBR)

Bucharest, 030463, Romania
Centro Medico de Estudios Clinicos y Farmacovigilancia (CECYF)

Buenos Aires, C1426ABP, Argentina
Centro de Estudios Clinicos Victoria Limitada (Cevic)

Victoria, 4720000, Chile
Centro de Investigaciones Médicas Tucumán

San Miguel de Tucumán, Tucumán Province, T4000AXL, Argentina
Centro de Investigación y Prevención Cardiovascular-Arenales

Buenos Aires, C1061, Argentina
Centro de Investigación y Tratamiento Reumatológico S.C

Miguel Hidalgo, 11850, Mexico
Centro de especialidades médicas Vanguardia

Temuco, 4810345, Chile
Centrum Medyczne Plejady

Krakow, 30-363, Poland
Chapel Allerton Hospital

Leeds, LS7 4SA, United Kingdom
ClinHouse Centrum Medyczne

Zabrze, 41-807, Poland
Clinical Research Chile SpA

Valdivia, 683, Chile
Colentina Clinical Hospital

Bucharest, 020125, Romania
Consultora Integral de Salud Centro Médico Privado

Córdoba, X5000KEH, Argentina
Consultorios Médicos Dr. Doreski

Buenos Aires, C1426, Argentina
Corporacio Sanitaria Parc Tauli

Barcelona, 08208, Spain
Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus

Debrecen, 4032, Hungary
Dermacross Clinica Dermatologica

Vitacura, 7640881, Chile
Dr I Cantacuzino Clinical Hospital

Bucharest, 030167, Romania
Enroll SpA

Santiago, 8320000, Chile
Haywood Community Hospital

Stoke-on-Trent, ST6 7AG, United Kingdom
Hiperdia Romania

Bucharest, 41303, Romania
Hospital General de Agudos Dr. José María Ramos Mejia

Buenos Aires, C1221AFC, Argentina
Hospital Quironsalud Infanta Luisa

Seville, 41010, Spain
Hospital de La Santa Creu i Sant Pau

Barcelona, 08025, Spain
IRIS Research and Development LLC

Plantation, Florida, 33324, United States
Institute of Rheumatology - PPDS

Belgrade, 11000, Serbia
Instituto CER S.A.

Quilmes, B1878DVB, Argentina
Instituto de Investigación Clínica TyT

Buenos Aires, C1405BFN, Argentina
Klinika Reuma Park sp . zoo Sp.k.

Warsaw, 02-665, Poland
M2M Med-ul.

Chorzów, 41-500, Poland
MICS Centrum Medyczne Warszawa

Warsaw, B1000-874, Poland
Malopolskie Badania Kliniczne Sp. z o.o.

Krakow, 30-002, Poland
Malopolskie Centrum Kliniczne

Krakow, 30-149, Poland
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mediadvance Clinical

Chihuahua City, 31203, Mexico
Medical Care and Research S.A. de C.V.

Mérida, 97070, Mexico
Military Medical Academy

Belgrade, 11000, Serbia
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji

Warsaw, 02-637, Poland
Ninewells Hospital

Dundee, DD2 1SG, United Kingdom
Oaxaca Site Management Organization - Clinic - OSMO - PPDS

Oaxaca City, 68000, Mexico
Organización Médica de Investigación

Buenos Aires, C1015, Argentina
PanAmerican Clinical Research

Guadalajara, 44670, Mexico
Policlinica SelfMed Clinique

Timișoara, 300133, Romania
Pécsi Tudomanyegyetem - Vasvari Pal u.

Pécs, 7622, Hungary
Rheumatology Associates

Arlington, Texas, 76012, United States
Royal Free Hospital

London, NW3 2QG, United Kingdom
Royal National Hospital for Rheumatic Diseases

Bath, BA1 3NG, United Kingdom
STAT Research S.A.

Buenos Aires, Buenos Aires, C1023, Argentina
Santa Familia PTG Łódź

Lodz, 90-003, Poland
Sf.Maria Clinical Hospital

Bucharest, 11172, Romania
Twoja Przychodnia NCM

Nowa Sól, 67-100, Poland
Twoja Przychodnia PCM - ul.

Poznan, 60-324, Poland
UCLA Department of Medicine

Los Angeles, California, 90024, United States
UCSD Altman Clinical and Translational Research Institute Center for Clinical Research

La Jolla, California, 92037, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Michigan Hospital

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.